Testing a new immunotherapy combo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial is testing two immunotherapy drugs (balstilimab and botensilimab) to see if they can shrink tumors in people with advanced pancreatic cancer that has worsened after at least one prior treatment. If you have microsatellite stable (MSS) disease, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pancreatic cancer (adenocarcinoma) that has spread or can't be removed surgically.
- Your cancer has the 'MSS' (microsatellite stable) type, meaning it does not have a specific genetic instability
- Your cancer has grown or spread after at least one prior line of chemotherapy or other systemic therapy.
- You are generally healthy enough to carry out daily activities (ECOG 0 or 1).
- You have not had radiation to the liver, and the amount of tumor in your liver is not too high (≤25% of your liver volume).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (serplulimab and bevacizumab) plus two different chemotherapy regimens for people with advanced pancreatic cancer that has worsened after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.